"Forebyggelse af kardiovaskulære hændelser hos patienter med type 2- diabetes og én yderligere risikofaktor samt normalt til let forhøjet kolesteroltal uden klinisk evident koronar hjertesygdom",
In the Final Assessment report (1 November 2005) the Reference Member State proposed, and the MAH agreed to, the following indication: “ Prevention of cardiovascular events in patients with type 2 diabetes and one additional risk factor with normal to mildly elevated cholesterol level without clinically evident coronary heart disease”.